Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Tiziana Life Sciences LtdNASDAQ: TLSA
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income grows 122.2% year over year
Q4 FY2025 net income of $12.8M (cash outflow) rose 122.2% year over year. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$9.45M (-48.7%) for the fiscal year ending Dec 2026, a slowdown from the +94.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$12.8M— QoQ
- Last fiscal yearDec 2025
- -$18.43M+94.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +122.2% | — | — |
| 1 year | +94.4% | -48.7% | -143.1 pp |
| 3-year CAGR | +13.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (18.43M) USD
- Year-over-year change
- -94.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.43M) | -94.4% |
| FY2024 | 2024-12-31 | (9.48M) | +32.3% |
| FY2023 | 2023-12-31 | (14M) | -11.5% |
| FY2022 | 2022-12-31 | (12.55M) | +27.7% |
| FY2021 | 2021-12-31 | (17.36M) | — |
Net Income vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 net income of $18.43M is the 7th largest of the 9 companies compared; the peer median is $28.05M.
- Its year-over-year change of +94.4% is the highest of 9, against a peer median of -10.7%.
- Over three fiscal years its annual growth of +13.7% compares with a peer median of +7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.13M | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $113.22M | -48.4% | +6.6% | — | |
| LTM Mar 2026 | $70.36M | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $34.98M | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $21.13M | +23.3% | +20.1% | 266.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M | -67.7% | -30.2% | 288.3% |
| FY2025 | $18.43M | +94.4% | +13.7% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $9.67M | +44.2% | +87.2% | — |
| FY2025 | $7.97M | -52.6% | +8.6% | — | |
| Peer median (excluding TLSA) | $28.05M | -10.7% | +7.6% | 266.1% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.36M) | (12.55M) | (14M) | (9.48M) | (18.43M) |
| Depreciation & Amortization | 104.52K | 41.57K | 75.97K | 99.09K | 234K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (573.01K) | (948.89K) | (1.25M) | (441.1K) | 3.06M |
| Accounts Receivables | 317.27K | (127.17K) | (1.14M) | (1.11M) | (692K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (890.27K) | (821.72K) | (109.21K) | 670.44K | 3.75M |
| Other Non-Cash Items | 1.7M | (2.53M) | 2.75M | 8.6M | 2.29M |
| Operating Cash Flow | (16.13M) | (15.99M) | (12.42M) | (1.22M) | (12.85M) |
| Capital Expenditures | (16.31K) | 0 | 0 | (15.18K) | (21K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (2.18M) | (791.35K) | (52K) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112.67K | (1.08M) | (200.21K) | 10.45K | 3.06M |
| Investing Cash Flow | 96.37K | (3.26M) | (991.57K) | (56.74K) | 3.04M |
| Debt Repayment | 0 | 0 | 0 | (141K) | 0 |
| Common Stock Issued | 95.62K | 0 | 125.83K | 3.71M | 10.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.67K) | (44.84K) | (94.17K) | 28.33K | (196K) |
| Financing Cash Flow | (17.05K) | (44.84K) | 31.65K | 3.6M | 10.01M |
| Effect of Forex Changes | (1.53M) | (324.45K) | (22.16K) | (293.27K) | 84K |
| Net Change in Cash | (17.59M) | (19.62M) | (13.4M) | 2.03M | 286K |
| Free Cash Flow | (16.15M) | (15.99M) | (12.42M) | (1.23M) | (12.87M) |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.